| Field |
Value |
Language |
|
dc.contributor.author |
Yang, B |
|
|
dc.contributor.author |
Sang, R |
|
|
dc.contributor.author |
Li, Y |
|
|
dc.contributor.author |
Goldys, E |
|
|
dc.contributor.author |
Deng, W
https://orcid.org/0000-0002-9413-0978
|
|
|
dc.date.accessioned |
2025-01-10T05:22:18Z |
|
|
dc.date.available |
2025-01-10T05:22:18Z |
|
|
dc.date.issued |
2024-03-22 |
|
|
dc.identifier.citation |
Cancer Research, 2024, 84, (6_Supplement), pp. 5743-5743 |
|
|
dc.identifier.issn |
0008-5472 |
|
|
dc.identifier.issn |
1538-7445 |
|
|
dc.identifier.uri |
http://hdl.handle.net/10453/183213
|
|
|
dc.description.abstract |
<jats:title>Abstract</jats:title>
<jats:p>In this study, we employed X-ray induced photodynamic therapy (X-PDT) for the treatment on triple negative breast cancer (TNBC) cells. To do this, we rationally developed a liposome delivery system co-loaded with protoporphyrin IX (PPIX) and perfluorooctyl bromide (PFOB). Low-dose X-ray at 2Gy was employed to activate PPIX for reactive oxygen species (ROS) generation, and the co-loading of PFOB provided additional oxygen to augment ROS production. The highly toxic ROS triggered TNBC cell death. In vitro X-PDT effects including intracellular ROS generation, cytotoxicity, cell viability and apoptosis/necrosis assay in TNBC cells were studied. Our results indicate that the nanocarriers effectively induced X-PDT effect with very low dose radiation, which makes it possible to damage cancer cells. Our strategy may offer a paradigm-shifting treatment alternative for TNBC patients who need neoadjuvant radiotherapy but wish to avoid long term detrimental effect on functional outcome by undergoing X-PDT using only a fraction of the conventional radiotherapy.</jats:p>
<jats:p>Citation Format: Biyao Yang, Rui Sang, Yi Li, Ewa Goldys, Wei Deng. Liposome platform enables X-ray induced photodynamic therapy treatment against human triple negative breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5743.</jats:p> |
|
|
dc.language |
en |
|
|
dc.publisher |
American Association for Cancer Research (AACR) |
|
|
dc.relation.ispartof |
Cancer Research |
|
|
dc.relation.isbasedon |
10.1158/1538-7445.am2024-5743 |
|
|
dc.rights |
info:eu-repo/semantics/closedAccess |
|
|
dc.subject |
1112 Oncology and Carcinogenesis |
|
|
dc.subject.classification |
Oncology & Carcinogenesis |
|
|
dc.subject.classification |
3101 Biochemistry and cell biology |
|
|
dc.subject.classification |
3211 Oncology and carcinogenesis |
|
|
dc.title |
Abstract 5743: Liposome platform enables X-ray induced photodynamic therapy treatment against human triple negative breast cancer cells |
|
|
dc.type |
Journal Article |
|
|
utslib.citation.volume |
84 |
|
|
utslib.for |
1112 Oncology and Carcinogenesis |
|
|
pubs.organisational-group |
University of Technology Sydney |
|
|
pubs.organisational-group |
University of Technology Sydney/Faculty of Engineering and Information Technology |
|
|
pubs.organisational-group |
University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering |
|
|
utslib.copyright.status |
open_access |
* |
|
dc.date.updated |
2025-01-10T05:22:17Z |
|
|
pubs.issue |
6_Supplement |
|
|
pubs.publication-status |
Published |
|
|
pubs.volume |
84 |
|
|
utslib.citation.issue |
6_Supplement |
|
